Last reviewed · How we verify
Breakthrough Pain in Opioid Tolerant Patients
Approved treatments
- Fentanyl (F2) · Oslo University Hospital
- Duragesic · Johnson & Johnson (Janssen Pharmaceutica)
Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Breakthrough Pain in Opioid Tolerant Patients patent landscape — cliff calendar, originator estates, attackable patents
- Breakthrough Pain in Opioid Tolerant Patients treatment landscape brief
- Breakthrough Pain in Opioid Tolerant Patients treatment updates RSS
Frequently asked questions about Breakthrough Pain in Opioid Tolerant Patients
What drugs treat Breakthrough Pain in Opioid Tolerant Patients?
Tracked treatments include Fentanyl (F2), Duragesic.
What is the treatment for Breakthrough Pain in Opioid Tolerant Patients?
Standard treatment for Breakthrough Pain in Opioid Tolerant Patients includes Fentanyl (F2), Duragesic. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Breakthrough Pain in Opioid Tolerant Patients patent cliff · Breakthrough Pain in Opioid Tolerant Patients CI report
- Treatment: Fentanyl (F2) · Oslo University Hospital
- Treatment: Duragesic · Johnson & Johnson (Janssen Pharmaceutica)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing